IPP Bureau
Erytech sells U.S. manufacturing facility and enters long-term supply agreement with Catalent
By IPP Bureau - April 25, 2022
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
Malaria cases and related deaths have reduced significantly: Dr Mansukh Mandaviya
By IPP Bureau - April 25, 2022
April 25th is commemorated as World Malaria Day
Doctors at Yashoda successfully treated advanced-stage laryngeal cancer
By IPP Bureau - April 25, 2022
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
Marskans Pharma acquires Dubai based Access Healthcare
By IPP Bureau - April 25, 2022
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
Thermo Fisher opens bioprocessing manufacturing site in Ogden, Utah
By IPP Bureau - April 25, 2022
The $44 million facility is part of Thermo Fisher's $650 million multi-year investment, announced last year, to help ensure flexible, scalable and reliable bioprocessing production capacity exists for critical materials used in developing new and existing biologics and vaccines, including for COVID-19
NovoSeven recommended for approval for the treatment of severe postpartum haemorrhage by the European Medicines Agency
By IPP Bureau - April 23, 2022
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
Twenty eight companies commit to Rs 6000 crore at Global Ayush meet
By IPP Bureau - April 23, 2022
The commitment is expected to generate over 5.56 lakh jobs and positively impact the lives of more than 76 lakh people, the ministry said
CHMP recommends EU approval of Roche’s Tecentriq as adjuvant treatment
By IPP Bureau - April 23, 2022
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
CHMP adopts positive opinion on Tabrecta for advanced non-small cell lung cancer
By IPP Bureau - April 23, 2022
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Novavax initiates Covid-19 booster study in adolescents in Phase 3 trial
By IPP Bureau - April 23, 2022
Continuation of pediatric expansion in adolescents of PREVENT-19 Phase 3 trial will evaluate safety and immunogenicity of a booster dose
Covid-19 vaccine protection against hospitalization wanes
By IPP Bureau - April 23, 2022
Kaiser Permanente finds the Pfizer Covid-19 third dose vaccine protection against hospitalization from omicron wanes after 3 months
IOL Chemicals and Pharmaceuticals commences commercial production of paracetamol
By IPP Bureau - April 23, 2022
All the capex is being met through internal accruals only
Brinton Pharmaceuticals to invest GBP 30 million for R&D centre in UK
By IPP Bureau - April 23, 2022
The proposed life sciences research and development centre in North of England region of UK will support acceleration of the company’s research in the areas of biotechnology, health and life sciences
WHO recommends Paxlovid for Covid-19 therapy
By IPP Bureau - April 22, 2022
This recommendation is based on new data from two randomized controlled trials involving 3078 patients
USFDA approves Phase 3 Acute Respiratory Distress Syndrome (ARDS), trial
By IPP Bureau - April 22, 2022
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
